Clinical trials: Lymphoma, Hodgkins
Lymphoma, B-Cell
External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma
The purpose of the research study is to learn whether external beam radiation can be used as a safe and effective treatment for patients with bulky (≥ 5cm) sites of non-Hodgkin's lymphoma prior to treatment with 90Y-ibritumomab…
- Trial name
- NCT00271050
- Testing
- external beam radiotherapy plus 90-Y ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Cleveland Clinic
Obstructive Sleep Apnea, Hodgkin Lymphoma
Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
While thoracic radiation therapy (TRT) has been a primary component in successful treatment of Hodgkin lymphoma, exposure to this treatment has been associated with significant cardiovascular, cerebrovascular, and pulmonary…
- Trial name
- NCT03361020
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced Solid Tumor, Non-Hodgkin's Lymphoma
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
The ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas.
- Conditions
- Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT03188965
- Testing
- Elimusertib (BAY1895344)
- Where
- 29 sites in United States, Canada and 5 more
- Volunteers
- 229 people
- Sponsor
- Bayer
Lymphoma
Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as chlorambucil, vinblastine, procarbazine, and prednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00417014
- Testing
- chlorambucil, prednisolone, procarbazine hydrochloride
- Volunteers
- 358 people
- Sponsor
- Children's Cancer and Leukaemia Group
Lymphoma
Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002676
- Testing
- carmustine, cyclophosphamide, cytarabine
- Where
- 21 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neoplasms, Non-Hodgkin Lymphoma
Study of TPI 287 in Patients With Advanced Malignancies
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material.
- Conditions
- Neoplasms, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT00113724
- Testing
- TPI 287 Injection
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Cortice Biosciences, Inc.
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic disease.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma
- Trial name
- NCT00719888
- Testing
- Cyclophosphamide, Cyclosporine, Double-Unit Umbilical Cord Blood Transplantation
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- Fred Hutchinson Cancer Center
NonHodgkin Lymphoma, Lymphoproliferative Disorders
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
Subjects have a type of a lymph node cancer called Non-Hodgkin's Lymphoma (NHL) or lymphoproliferative disease (LPD), which affects their immunity, blood production, and can involve multiple other organs in the body.
- Conditions
- NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma, EBV-Related PTLD
- Trial name
- PREVALE (NCT02973113)
- Testing
- EBVST Cells, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Baylor College of Medicine
Classical Hodgkin Lymphoma
Microenvironmental Trial of Classical Hodgkin Lymphoma in Adolescents
Background. Classical Hodgkin's lymphoma (cHL) in adolescents between 15 and 18 years shows a higher disease-related mortality and the overall prognosis is worse than both children and adults. Objectives.
- Trial name
- LH2004ME (NCT06814860)
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoma, Hodgkin Lymphoma
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan. Large B-cell lymphoma (LBCL) is the most common subtype of aggressive B-cell lymphoma.
- Conditions
- Lymphoma, Hodgkin Lymphoma, T-cell Lymphoma, Waldenstrom Macroglobulinaemia
- Trial name
- NCT06550427
- Testing
- ctDNA analyzed by phased variant
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Hodgkin Lymphoma
A Survey Exploring Health and Screening Tests in People Treated for Hodgkin Lymphoma
A survey of health beliefs and cancer screening behaviour and intentions in Hodgkin lymphoma survivors
- Trial name
- NCT04996862
- Where
- United Kingdom
- Volunteers
- 165 people
- Sponsor
- The Christie NHS Foundation Trust
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Hodgkin Lymphoma
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
This is a single-arm, phase II, multi-centre study of the safety and efficacy of the PD-1 inhibitor, nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell transplant (SCT) in relapsed/ refractory…
- Trial name
- ANIMATE (NCT03337919)
- Testing
- Nivolumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- University College, London
Diffuse Large B-cell Lymphoma
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)
The main objective of the trial is to assess the efficacy and tolerability of Lonca-R in unfit and frail participants with previously untreated DLBCL.
- Trial name
- LOTIS-9 (NCT05144009)
- Testing
- Loncastuximab Tesirine, Rituximab
- Where
- 41 sites in United States, Italy and 2 more
- Volunteers
- 41 people
- Sponsor
- ADC Therapeutics S.A.
Hodgkin Lymphoma
A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma
The purpose of this study is to test how safe and effective the research study drug, pembrolizumab is as a treatment for patients with Hodgkin lymphoma who have not previously been treated for this disease and are unsuitable for…
- Trial name
- PLIMATH (NCT03331731)
- Testing
- pembrolizumab
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 27 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Non-Hodgkin's Lymphoma
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
- Trial name
- NCT00285428
- Testing
- hA20-humanized anti-CD20 antibody
- Where
- 3 sites in United States
- Volunteers
- 82 people
- Sponsor
- Gilead Sciences
Acute Leukemia, Chronic Leukemia
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.
- Conditions
- Acute Leukemia, Chronic Leukemia, Multiple Myeloma, Hodgkin's Lymphoma
- Trial name
- NCT00273936
- Testing
- AVN-944 capsules for oral administration
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Lymphoma, Non-Hodgkin
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
This study is about a medicine called TAK-981 given with rituximab, used to treat adults with relapsed or refractory CD20-positive non-Hodgkin lymphoma. This study has 2 parts.
- Trial name
- NCT04074330
- Testing
- TAK-981, Rituximab
- Where
- 59 sites in United States, Canada and 7 more
- Volunteers
- 38 people
- Sponsor
- Takeda
DLBCL
A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
This is a prospective international, multi-center, randomized, double-blind controlled study designed to assess and compare the pharmacokinetics, pharmacodynamics and the safety of MabThera® and TL011, in combination with CHOP in…
- Trial name
- NCT01205737
- Testing
- TL011, Rituximab
- Where
- 41 sites in Bulgaria, Estonia and 8 more
- Volunteers
- 186 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
B-cell Lymphoma, Non Hodgkin Lymphoma
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies.
- Conditions
- B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT05653271
- Testing
- Cyclophosphamide, Fludarabine, ACE1831
- Where
- 13 sites in United States, Hong Kong and 1 more
- Volunteers
- 16 people
- Sponsor
- Acepodia Biotech, Inc.